Erschienen in:
01.01.2014 | Letter to the editor
Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children?
Results from a prospective multicenter double blind randomized controlled trial
verfasst von:
M. F. Raphael, A. M. den Boer, W. J. W. Kollen, H. Mekelenkamp, F. C. H. Abbink, G. J. L. Kaspers, K. Zomer-Kooijker, B. H. W. Molmans, W. J. E. Tissing
Erschienen in:
Supportive Care in Cancer
|
Ausgabe 1/2014
Einloggen, um Zugang zu erhalten
Excerpt
In pediatric oncology, chemotherapy- or radiotherapy-induced oral mucositis (OM) is accompanied by decreased oral intake, pain, analgesics use, and hospital admission [
1,
2]. Moreover, OM is correlated with an increased risk of sepsis [
3,
4]. Recently, Caphosol, a supersaturated Ca
2+/PO
4 3− mouth rinse, became available to prevent or treat mucositis [
5]. Papas et al. demonstrated Caphosol to have a beneficial prophylactic effect in adult hematopoietic stem cell transplantation (HSCT) patients, but evidence in pediatric patients is lacking [
6]. We studied whether Caphosol can be used to treat OM in a prospective randomized study. …